Skip to content
Search

Latest Stories

Occludin protein facilitates coronavirus spread in humans: Study

The findings hold promise for the development of future antiviral drugs aimed at targeting this protein and disrupting the spread of the coronavirus

Occludin protein facilitates coronavirus spread in humans: Study

Researchers from the University of Missouri, USA, have made a significant breakthrough by identifying occludin, a specific protein within the human body, as a crucial facilitator of coronavirus spread from cell to cell following infection.

The study, published in the journal Proceedings of the National Academy of Sciences, highlights how this protein acts as a mediator for the transmission of the virus between cells.


These findings hold promise for the development of future antiviral drugs aimed at targeting this protein and disrupting the spread of the coronavirus.

"This basic, scientific research is very important to better understand the underlying mechanisms of disease progression inside the body's cells so that the proper countermeasures can be identified and developed," said Wenjun Ma, an associate professor at the university and lead author of the study.

In their investigation of the coronavirus's cell-to-cell spread, the research team conducted a thorough analysis of cell samples. Their findings revealed that when the occludin protein within a single cell is compromised by the virus, it accelerates viral replication and facilitates the rapid transmission to adjacent cells within the body.

Consequently, this process exacerbates the infection and increases the likelihood of more severe symptoms.

The team emphasised the potential significance of this knowledge for the development of antiviral drugs.

By exploring the impact of antiviral medications on fortifying the occludin protein against infection, researchers aim to leverage this understanding to improve treatment strategies and potentially mitigate the virus's spread, Ma said.

Extensive analysis of cell samples by the research team has shed light on the intricate process of coronavirus transmission between cells. They discovered that while the virus initially infects a single cell, the complexity of cellular structures becomes evident as the occludin protein within the cell becomes damaged. This damage triggers rapid viral replication and facilitates the spread to neighbouring cells.

Ma stated, "For example, if only one cell in the lungs is infected at first, the ability to breathe may not be significantly impacted. "However, once the virus spreads to neighbouring cells throughout the lungs, it can lead to difficulty breathing and other respiratory problems.”

In the future, Ma intends to expand the scope of research by investigating the potential impact of other viral infections on the occludin protein. This endeavor aims to enhance our understanding of how various viruses interact at the cellular level with their host organisms.

(PTI)

More For You

Mounjaro price rise

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro

iStock

Mounjaro’s highest dose to rise from £122 to £247.50, not £330

Highlights:

  • Eli Lilly had announced a steep price rise of up to 170% for Mounjaro.
  • A new discount deal with UK suppliers will limit the increase for patients.
  • Pharmacies will still apply a mark-up, but consumer costs are expected to rise less than initially feared.
  • NHS pricing remains unaffected due to separate arrangements.

Eli Lilly has agreed a discounted supply deal for its weight-loss drug Mounjaro, easing fears of a sharp rise in costs for UK patients. The new arrangement means that, from September, pharmacies and private services will face smaller wholesale increases than first expected, limiting the impact on consumers.

Why the price rise was announced

Earlier this month, Eli Lilly said it would raise Mounjaro’s list price by as much as 170%, which could have pushed the highest monthly dose from £122 to £330. The company argued that UK pricing needed to align more closely with higher costs in Europe and the United States.

Keep ReadingShow less
chicken-pox-istock

The Department of Health said the rollout would reduce missed days at nursery and school, cut time parents take off work, and save the NHS about £15 million a year. (Representational image: iStock)

iStock

England to introduce free chickenpox vaccine for children from 2026

CHILDREN in England will be offered a free chickenpox vaccine for the first time from January 2026, the government has announced.

GP practices will give eligible children a combined vaccine for measles, mumps, rubella and varicella (MMRV) as part of the routine childhood vaccination schedule. Around half a million children each year are expected to be protected.

Keep ReadingShow less
Naga Munchetty urges women to prioritise their health

Naga Munchetty

Naga Munchetty urges women to prioritise their health

WHEN broadcaster and journalist Naga Munchetty began speaking openly about her experiences with adenomyosis and debilitating menstrual pain, the response was overwhelming.

Emails and messages poured in from women who had endured years of dismissal, silence and shame when it came to their health. That outpouring became the driving force behind her new book, It’s Probably Nothing, which calls for women to be heard and to advocate for themselves in a medical system that has too often ignored them.

Keep ReadingShow less
London temple project for Shree Banke Bihari launched

London temple project for Shree Banke Bihari launched

Mahesh Liloriya

The Shree Kunj Bihari Vrindavan (UK) Temple has officially launched its project to establish a grand home for Shree Banke Bihari in London.

The inaugural event, held in Harrow from 4 pm, featured devotional chants, the Deep Pragtya ceremony, and a presentation outlining the temple’s vision. Speaking at the gathering, Shalini Bhargava described the planned temple as “a spiritual home promoting bhakti, unity and seva for generations to come.”

Keep ReadingShow less
Dickie and Watt

Dickie and Watt launched BrewDog at the age of 24

Getty Images

BrewDog co-founder Martin Dickie leaves after 17 years as James Watt steps back

Highlights:

  • Martin Dickie has announced his departure from BrewDog and the alcohol industry.
  • He co-founded the Ellon-based brewer with James Watt in 2007.
  • Dickie cited family time and personal reasons for his exit.
  • His departure follows recent bar closures as part of a company restructuring.
  • BrewDog confirmed no further leadership changes will follow.

BrewDog co-founder Martin Dickie has announced he is leaving the Scottish brewer and the wider alcohol industry for “personal reasons.” Dickie, who founded the Ellon-based business with James Watt in 2007, said he wanted to spend more time with his family after more than two decades in brewing and distilling.

Early beginnings

Dickie and Watt launched BrewDog at the age of 24, starting from a garage in Fraserburgh and selling hand-filled bottles from a van at local markets. The company grew rapidly to become one of the UK’s best-known craft brewers.

Keep ReadingShow less